litlas
Log inCreate account

Sattva S. Neelapu

Active 2005–2025

205
Papers
39,208
Citations
84
h-index
196
i10-index

Citations

Citations per year for Sattva S. Neelapu1990: 2 citations1991: 1 citations1992: 1 citations1997: 1 citations2001: 3 citations2005: 4 citations2006: 6 citations2007: 7 citations2008: 16 citations2009: 22 citations2010: 35 citations2011: 41 citations2012: 74 citations2013: 77 citations2014: 111 citations2015: 134 citations2016: 129 citations2017: 182 citations2018: 324 citations2019: 1,234 citations2020: 2,139 citations2021: 2,670 citations2022: 2,529 citations2023: 2,171 citations2024: 3,442 citations2025: 1,816 citations2026: 53 citations1993–1996: no citations, so these years are not shown1998–2000: no citations, so these years are not shown2002–2004: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,947 citing papers, 30.8% of this breakdownChina: 2,079 citing papers, 12.9% of this breakdownGermany: 1,007 citing papers, 6.3% of this breakdownUnited Kingdom: 834 citing papers, 5.2% of this breakdownItaly: 730 citing papers, 4.5% of this breakdownFrance: 699 citing papers, 4.4% of this breakdownSpain: 549 citing papers, 3.4% of this breakdownCanada: 488 citing papers, 3% of this breakdownAustralia: 408 citing papers, 2.5% of this breakdownSwitzerland: 386 citing papers, 2.4% of this breakdownJapan: 343 citing papers, 2.1% of this breakdownNetherlands: 337 citing papers, 2.1% of this breakdown
0%30.8%Other 20.4%

Institutions

Fields

  • Medicine74.5%
  • Immunology and Microbiology13.2%
  • Biochemistry, Genetics and Molecular Biology10%
  • Engineering1.1%
  • Neuroscience0.2%
  • Computer Science0.2%
  • Other0.8%

Topics

  • CAR-T cell therapy research20.4%
  • Immune Cell Function and Interaction7.9%
  • Lymphoma Diagnosis and Treatment5.8%
  • Virus-based gene therapy research4.3%
  • Immunotherapy and Immune Responses4.2%
  • Cancer Immunotherapy and Biomarkers3.8%
  • Other53.6%

Coauthors

All papers

Open in search
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 cited by 5,915

  2. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

    Authors: Daniel W. Lee, Bianca Santomasso, Frederick L. Locke, Armin Ghobadi, Cameron J. Turtle, Jennifer N. Brudno, Marcela V. Maus, Jae H. Park, Elena Mead, Steven Z. Pavletic, William Y. Go, Lamis Eldjerou, Rebecca Gardner, Noelle V. Frey, Kevin J. Curran, Karl S. Peggs, Marcelo C. Pasquini, John F. DiPersio, Marcel R.M. van den Brink, Krishna V. Komanduri, Stephan A. Grupp, Sattva S. Neelapu - Biology of Blood and Marrow Transplantation 2018 cited by 3,445

  3. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Authors: Enli Liu, David Marín, Pinaki P. Banerjee, Homer A. Macapinlac, Philip A. Thompson, Rafet Başar, Lucila Nassif Kerbauy, Bethany Overman, Peter F. Thall, Mecit Kaplan, Vandana Nandivada, Indresh Kaur, Ana Karen Nunez Cortes, Kai Cao, May Daher, Chitra Hosing, Evan N. Cohen, Partow Kebriaei, Rohtesh S. Mehta, Sattva S. Neelapu, Yago Nieto, Michael Wang, William G. Wierda, Michael J. Keating, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani - New England Journal of Medicine 2020 cited by 2,139

  4. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

    Authors: Emma Morris, Sattva S. Neelapu, Theodoros Giavridis, Michel Sadelain - Nature reviews. Immunology 2021 cited by 1,039

  5. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    Authors: Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jaeyeon Kim, William Y. Go, Sattva S. Neelapu - The Lancet Oncology 2018 cited by 2,251

  6. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Authors: Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Cristina Gutiérrez, Frederick L. Locke, Krishna V. Komanduri, Yi Lin, Nitin Jain, Naval Daver, Jason R. Westin, Alison Gulbis, Monica Loghin, John de Groot, Sherry Adkins, Suzanne E. Davis, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall - Nature Reviews Clinical Oncology 2017 cited by 2,380

  7. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

    Authors: Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal, Basem M. William, Javier Muñoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub‐Agha, Olalekan O. Oluwole, Henry C. Fung, Joseph D. Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu - The Lancet Oncology 2021 cited by 617

  8. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

    Authors: Qing Deng, Guangchun Han, Nahum Puebla‐Osorio, Man Chun John, Paolo Strati, Beth Chasen, Enyu Dai, Minghao Dang, Neeraj Jain, Haopeng Yang, Yuanxin Wang, Shaojun Zhang, Ruiping Wang, Runzhe Chen, Jordan Showell, Sreejoyee Ghosh, Sridevi Patchva, Qi Zhang, Ryan Sun, Frederick Hagemeister, Luis Fayad, Felipe Samaniego, Hans C. Lee, Loretta J. Nastoupil, Nathan Fowler, R. Eric Davis, Jason R. Westin, Sattva S. Neelapu, Linghua Wang, Michael R. Green - Nature Medicine 2020 cited by 595

  9. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

    Authors: Michael Crump, Sattva S. Neelapu, Umar Farooq, Éric Van Den Neste, John Kuruvilla, Jason R. Westin, Brian K. Link, Annette E. Hay, James R. Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew J. Maurer, Lynn Navale, Jeff Wiezorek, William Y. Go, Christian Gisselbrecht - Blood 2017 cited by 1,683

  10. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    Authors: Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, André Goy, Brian T. Hill, Khoan Vu, Charalambos Andreadis, Javier Muñoz, Jason R. Westin, Julio C. Chávez, Amanda F. Cashen, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke - Journal of Clinical Oncology 2020 cited by 786

  11. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome

    Authors: Melissa Hines, Tristan Knight, Kevin O. McNerney, Mark B. Leick, Tania Jain, Sairah Ahmed, Matthew J. Frigault, Joshua A. Hill, Michael D. Jain, William T. Johnson, Yi Lin, Kris M. Mahadeo, Gabriela Marón, Rebecca Marsh, Sattva S. Neelapu, Sarah Nikiforow, Amanda K. Ombrello, Nirav N. Shah, Aimee C. Talleur, David P Turicek, Anant Vatsayan, Sandy W. Wong, Marcela V. Maus, Krishna V. Komanduri, Nancy Berliner, Jan‐Inge Henter, Miguel‐Angel Perales, Noelle V. Frey, David T. Teachey, Matthew J. Frank, Nirali N. Shah - Transplantation and Cellular Therapy 2023 cited by 304

  12. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

    Authors: Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot - Blood Advances 2020 cited by 455

  13. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

    Authors: Christoph K. Stein‐Thoeringer, Neeraj Saini, Eli Zamir, Viktoria Blumenberg, Maria‐Luisa Schubert, Uria Mor, Matthias Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayase, Roman Rohrbach, Chia‐Chi Chang, Lauren McDaniel, Ivonne I. Flores, Rogier Gaiser, Matthias Edinger, Daniel Wolff, Martin Heidenreich, Paolo Strati, Ranjit Nair, Dai Chihara, Luis Fayad, Sairah Ahmed, Swaminathan P. Iyer, Raphaël Steiner, Preetesh Jain, Loretta J. Nastoupil, Jason R. Westin, Reetakshi Arora, Michael Wang, Joel G. Turner, Meghan Menges, Melanie J. Hidalgo-Vargas, Kayla Reid, Peter Dreger, Anita Schmitt, Carsten Müller‐Tidow, Frederick L. Locke, Marco L. Davila, Richard E. Champlin, Christopher R. Flowers, Elizabeth J. Shpall, Hendrik Poeck, Sattva S. Neelapu, Michael Schmitt, Marion Subklewe, Michael D. Jain, Robert R. Jenq, Eran Elinav - Nature Medicine 2023 cited by 226

  14. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    Authors: Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jaeyeon Kim, Yan Zheng, Frederick L. Locke - Blood 2023 cited by 228

  15. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

    Authors: Sattva S. Neelapu, Michael Dickinson, Javier Muñoz, Matthew L. Ulrickson, Catherine Thiéblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, Hairong Xu, Julio C. Chávez - Nature Medicine 2022 cited by 283

  16. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions

    Authors: Yeonseok Chung, Shinya Tanaka, Fuliang Chu, Roza Nurieva, Gustavo Martínez, Seema Rawal, Yi-Hong Wang, Hoyong Lim, Joseph M. Reynolds, Xiao-hui Zhou, Hui-min Fan, Zhong-ming Liu, Sattva S. Neelapu, Chen Dong - Nature Medicine 2011 cited by 1,096

  17. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

    Authors: Nathalie Scholler, Régis Perbost, Frederick L. Locke, Michael D. Jain, Sarah Turcan, Corinne Danan, Edmund C. Chang, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jaeyeon Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M. Rossi, Adrian Bot, Jérôme Galon - Nature Medicine 2022 cited by 198

  18. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

    Authors: Marcela V. Maus, S. Alexander, Michael R. Bishop, Jennifer N. Brudno, Colleen Callahan, Marco L. Davila, Claudia Diamonte, Jörg Dietrich, Julie C. Fitzgerald, Matthew J. Frigault, Terry J. Fry, Jennifer Holter‐Chakrabarty, Krishna V. Komanduri, Daniel W Lee, Frederick L. Locke, Shannon L. Maude, Philip L. McCarthy, Elena Mead, Sattva S. Neelapu, Tomas G. Neilan, Bianca Santomasso, Elizabeth J. Shpall, David T. Teachey, Cameron J. Turtle, Tom Whitehead, Stephan A. Grupp - Journal for ImmunoTherapy of Cancer 2020 cited by 269

  19. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

    Authors: Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier Muñoz, Saurabh Dahiya, Amer Beitinjaneh, Miriam T. Jacobs, Joseph P. McGuirk, Julie M. Vose, André Goy, Charalambos Andreadis, Brian T. Hill, Kathleen Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros J. Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael Wang, Michael D. Jain - Journal of Clinical Oncology 2023 cited by 176

  20. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

    Authors: Vicki Plaks, John M. Rossi, Justin Chou, Linghua Wang, Soumya Poddar, Guangchun Han, Zixing Wang, Shao-Qing Kuang, Fuliang Chu, R. Eric Davis, Francisco Vega, Zahid Bashir, Caron A. Jacobson, Frederick L. Locke, Patrick M. Reagan, Scott J. Rodig, Lazaros J. Lekakis, Ian W. Flinn, David B. Miklos, Adrian Bot, Sattva S. Neelapu - Blood 2021 cited by 189

  21. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

    Authors: Paolo Strati, Sairah Ahmed, Fateeha Furqan, Luis Fayad, Hun Ju Lee, Swaminathan P. Iyer, Ranjit Nair, Loretta J. Nastoupil, Simrit Parmar, Maria Alma Rodriguez, Felipe Samaniego, Raphaël Steiner, Michael Wang, Chelsea C. Pinnix, Sandra B. Horowitz, Lei Feng, Ryan Sun, Catherine M. Claussen, Misha Hawkins, Nicole Johnson, Prachee Singh, Haleigh Mistry, Swapna Johncy, Sherry Adkins, Partow Kebriaei, Elizabeth J. Shpall, Michael R. Green, Christopher R. Flowers, Jason R. Westin, Sattva S. Neelapu - Blood 2021 cited by 214

  22. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    Authors: Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y. Go - Molecular Therapy 2017 cited by 619

  23. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

    Authors: Koichi Takahashi, Feng Wang, Hagop M. Kantarjian, Doss Denaha, Kanhav Khanna, Erika J. Thompson, Li Zhao, Keyur P. Patel, Sattva S. Neelapu, Curtis Gumbs, Carlos E. Bueso‐Ramos, Courtney D. DiNardo, Simona Colla, Farhad Ravandi, Jianhua Zhang, Xuelin Huang, Xifeng Wu, Felipe Samaniego, Guillermo Garcia‐Manero, P. Andrew Futreal - The Lancet Oncology 2016 cited by 400

  24. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

    Authors: Sattva S. Neelapu, Julio C. Chávez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub‐Agha, Rashmi Khanal, Joseph D. Rosenblatt, Ronald L. Korn, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, A. Scott Jung, Harry Miao, Sara Beygi, Caron A. Jacobson - Blood 2023 cited by 141